GlassScriptPhysician profile
Jim Christensen
NPI 1700830015
$5,259.73
in general payments reported to CMS, 2019-2025
35 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,913 · 2020: $1,001 · 2021: $1,034 · 2024: $19.93 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $975.01 | 2019-2025 | Shingrix, Arexvy, Nucala |
| Csl Behring | $588.36 | 2019-2021 | |
| Viiv Healthcare Company | $461.42 | 2019-2021 | |
| Genzyme Corporation | $310.45 | 2019-2021 | |
| Pfizer INC. | $308.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $288.87 | 2019-2021 | |
| Pharming Healthcare, INC. | $258.32 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $237.49 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.84 | 2020-2021 | |
| Shire North American Group INC | $220.07 | 2019 | |
| Octapharma USA, INC. | $182.70 | 2019-2021 | |
| Genentech USA, INC. | $149.99 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $147.30 | 2019-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $129.78 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $103.97 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $75.92 | 2019-2020 | |
| Janssen Biotech, INC. | $68.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.74 | 2020-2021 | |
| Bio Products Laboratory USA, INC. | $50.82 | 2019-2021 | |
| Lilly USA, LLC | $44.86 | 2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $36.08 | 2025 | Wegovy |
| Electromed, INC. | $34.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.44 | 2019 | |
| Dexcom, INC. | $30.84 | 2025 | Dexcom G6 Transmitter |
| Biocryst US Sales Co., LLC | $30.61 | 2021 | |
| Abbvie INC. | $28.92 | 2021 | |
| Gilead Sciences, INC. | $24.26 | 2019 | |
| Grifols USA, LLC | $23.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.26 | 2021 | |
| Advanced Respiratory, INC | $20.09 | 2019 | |
| Biogen, INC. | $19.93 | 2024 | Spinraza |
| Celgene Corporation | $16.83 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.70 | 2025 | Zoryve |
| Insmed, INC. | $14.35 | 2020 | |
| Astellas Pharma US INC | $13.76 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.